Ameriprise Financial Inc. boosted its stake in Haemonetics Corp. (NYSE:HAE) by 8.3% during the second quarter, Holdings Channel reports. The institutional investor owned 316,311 shares of the company’s stock after buying an additional 24,245 shares during the period. Ameriprise Financial Inc. owned approximately 0.62% of Haemonetics Corp. worth $9,173,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Los Angeles Capital Management & Equity Research Inc. bought a new position in Haemonetics Corp. during the second quarter worth $948,000. Fuller & Thaler Asset Management Inc. raised its position in Haemonetics Corp. by 17.1% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,134,641 shares of the company’s stock worth $61,883,000 after buying an additional 311,959 shares during the period. Airain ltd bought a new position in Haemonetics Corp. during the second quarter worth $1,010,000. Heartland Advisors Inc. bought a new position in Haemonetics Corp. during the second quarter worth $7,498,000. Finally, California Public Employees Retirement System raised its position in Haemonetics Corp. by 4.3% in the second quarter. California Public Employees Retirement System now owns 102,700 shares of the company’s stock worth $2,977,000 after buying an additional 4,200 shares during the period. 98.64% of the stock is owned by hedge funds and other institutional investors.
Shares of Haemonetics Corp. (NYSE:HAE) traded up 0.08% during mid-day trading on Monday, reaching $36.24. The company’s stock had a trading volume of 91,377 shares. The firm’s 50 day moving average is $36.67 and its 200 day moving average is $32.41. The firm’s market cap is $1.86 billion. Haemonetics Corp. has a one year low of $25.98 and a one year high of $38.06.
Haemonetics Corp. (NYSE:HAE) last announced its quarterly earnings results on Monday, August 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The firm earned $210 million during the quarter, compared to analysts’ expectations of $205.41 million. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.35 EPS. On average, equities analysts anticipate that Haemonetics Corp. will post $1.44 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the company. CJS Securities lowered Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price objective for the company. in a research report on Tuesday, September 20th. Sidoti lowered Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research report on Monday, August 15th. Zacks Investment Research lowered Haemonetics Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Barrington Research lowered Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 3rd. Finally, Jefferies Group raised their price objective on Haemonetics Corp. from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $34.50.
In related news, Director Ronald Merriman sold 4,337 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $35.14, for a total value of $152,402.18. Following the completion of the sale, the director now owns 22,088 shares in the company, valued at $776,172.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Simon purchased 60,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The stock was purchased at an average price of $35.00 per share, with a total value of $2,100,000.00. The disclosure for this purchase can be found here. 1.50% of the stock is owned by corporate insiders.
Haemonetics Corp. Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corp. (NYSE:HAE).
Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.